ANDDI-PRENATOME - Feasibility Study for a " Fast " Pangenomic High Throughput Sequencing Analysis in Prenatal Diagnosis (AnddiPrenatome)

• ClinicalTrials.gov Identifier: NCT03964441
• Recruitment Status: Recruiting
• First Posted: May 28, 2019
• Last Update Posted: June 22, 2022
• Sponsor: Centre Hospitalier Universitaire Dijon
• Information provided by (Responsible Party): Centre Hospitalier Universitaire Dijon

Tracking Information

• First Submitted Date: May 22, 2019
• First Posted Date: May 28, 2019
• Last Update Posted Date: June 22, 2022
• Actual Study Start Date: June 20, 2019
• Estimated Primary Completion Date: July 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 22, 2019)

• Time required to return ES results to patients and their families in a context prenatal diagnosis [ Time Frame: Through study completion, an average of 12 months ]
• number of discrepancies between ES and WGS [ Time Frame: Through study completion, an average of 12 months ]

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: July 8, 2021)

• Questionnaire to understand the expectations of couples and their a priori perception of ES [ Time Frame: Through study completion, an average of 12 months ]
  To define feelings and to know better how couples perceive ES and its implications and in particular the risk of discovery of VUS (variants of unknown significance) and ID (incidental data).
• Questionnaire to evaluate the organization of health professionals involved in the decision-making process [ Time Frame: Through study completion, an average of 12 months ]

• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: ANDDI-PRENATOME - Feasibility Study for a " Fast " Pangenomic High Throughput Sequencing Analysis in Prenatal Diagnosis
• Official Title: ANDDI-PRENATOME - Feasibility Study for a " Fast " Pangenomic High Throughput Sequencing Analysis in Prenatal Diagnosis

Brief Summary

Prenatal diagnosis of genetic diseases is a real medical challenge. The discovery of antenatal abnormalities on ultrasound is frequent (5 to 10% of pregnancies), and when an abnormalities is seen on ultrasound, it raises the possibility of an underlying developmental anomaly. Currently, in France, when abnormalities are discovered with an ultrasound scan, the etiological diagnosis is based on additional imaging tests (cerebral MRI, 3D bone tomography, fetal CT, fetal CT) or diagnostic tests such as invasive chorionic villus sampling, amniocentesis or fetal blood for infectious, metabolic, immunological and genetic investigations (standard karyotype, FISH (fluorescence in situ hybridization) for the rapid detection of aneuploidy, Chromosome Analysis on DNA Chip (ACPA or CGH-array) and possible sequencing of targeted genes when they are available within a time frame compatible with pregnancy). NIPT (Non-invasive prenatal testing) on cell free fetal DNA circulating in maternal blood has more limited indications, allowing, from an early stage of pregnancy, the determination of fetal sex and fetal rhesus factor and the search for aneuploidy.

However, establishing an etiological diagnosis during pregnancy has many benefits for the parents: clarifying the cause, obtaining a more precise prognosis to determine future management and outcome of the pregnancy, and establishing the risks of recurrence.

Over the past decade, medical genetics has undergone a real technological revolution, leading to the development of high throughput genome-wide, exome (ES) and genome (GS) sequencing. However, few countries have currently embarked on ES/GS in prenatal care, due to the constraints of time and the difficulty of interpreting genomic data when the clinical data is limited to antenatal imaging data.

In 2016, France launched the France Medicine Genomics 2025 Plan (PFMG2025) to deploy GS, particularly in the diagnosis of rare diseases. It is thus becoming essential to define the modalities of prescription of this testing, in particular during prenatal diagnosis. In parallel, from the first publications, the applications of genomic analysis on circulating fetal DNA seem to be able to extend to genome sequencing for research of SNVs responsible for developmental diseases.

The AnDDI-rares health network therefore proposes this ANDDI-PRENATOME pilot project to study the feasibility of a "rapid" analysis of ES in prenatal diagnosis from 61 fetuses with ultrasound abnormalities, as a first step before considering future cost-effectiveness (PRME) or care system performance (PREPS) studies in conjunction with the PFMG2025.

• Detailed Description: Not Provided
• Study Type: Observational
• Study Design: Observational Model: Cohort; Time Perspective: Prospective
• Target Follow-Up Duration: Not Provided
• Biospecimen: Not Provided
• Sampling Method: Non-Probability Sample
• Study Population: Pregnant women with antenatal discovery of at least two obstetrical ultrasound abnormalities

Condition

• Prenatal
• Genome-wide High Throughput Sequencing

Intervention

• Biological: Invasive fetal sampling, blood sampling of mother and father
  to perform an exome sequencing analysis in trio
• Biological: blood sampling from the mother to recover the circulating cell free fetal DNA
  to perform a sequencing analysis of the genome of circulating free fetal DNA
• Other: Parent interviews (optional organizational study)
  Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results
• Other: parent questionnaire (optional organizational study)
  To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results
• Other: professional interviews (optional organizational study)
  interview to understand how the decision is formed
• Other: Focus group for professionals (optional organizational study)
  interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.

Study Groups/Cohorts

• control
  fetus with at least 2 ultrasound abnormalities and both parents
  Interventions:

  • Biological: Invasive fetal sampling, blood sampling of mother and father
  • Other: Parent interviews (optional organizational study)
  • Other: parent questionnaire (optional organizational study)
• comparison
  fetus with at least 2 ultrasound abnormalities with ES diagnosis on invasive fetal sampling
  Interventions:

  • Biological: Invasive fetal sampling, blood sampling of mother and father
  • Biological: blood sampling from the mother to recover the circulating cell free fetal DNA
  • Other: Parent interviews (optional organizational study)
  • Other: parent questionnaire (optional organizational study)
• professional
  obstetrician, midwife, geneticist, biologist
  Interventions:

  • Other: professional interviews (optional organizational study)
  • Other: Focus group for professionals (optional organizational study)

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: July 8, 2021): 150
• Original Estimated Enrollment (submitted: May 22, 2019): 61
• Estimated Study Completion Date: July 2024
• Estimated Primary Completion Date: July 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Pregnant women with antenatal discovery of at least two obstetric ultrasound abnormalities (2 major malformations, or 1 major malformation and 1 minor malformation, or 1 isolated malformation with a high probability of a genetic condition) : who undergo invasive antenatal sampling for CGH-array diagnosis ; who has already had an invasive antenatal sampling for the diagnosis of CGH-array and for which the fetal CGH-array has been found to be normal (sufficient fetal DNA or amniotic fluid should be available to allow exome sequencing to be performed without further amniotic fluid puncture).
• Pregnant woman and father aged 18 years or more
• Written consent provided by the pregnant woman and the father of the fetus
• Possibility of sufficient fetal specimen (amniotic fluid or fetal blood) to collect an additional sample for the pilot project
• Possibility of sampling the pregnant woman and the father of the foetus (peripheral blood)
• Pregnant woman and father of the fetus able to understand the study

Pilot Organizational Study:

In addition to the inclusion & exclusion criteria of the main study:

• Pregnant woman and biological father of fetus who provided oral consent to be interviewed
• Professionals (obstetrician, midwife, geneticist, biologist) agreeing to be interviewed

Exclusion Criteria:

• Diagnostic hypothesis considered highly probable that can be confirmed by an available molecular or cytogenetic test with a lower cost than ES (e. g. 22q11 microdeletion) or high suspicion of fetal infection (e. g. toxoplamosis seroconversion)
• Refusal of pregnant woman or father of fetus to participate in the study
• Pregnancy earlier than 15 weeks of amenorrhea or later than 34 weeks of amenorrhea
• Pregnant woman and father of the foetus not covered by the national health insurance system
• Pregnant woman and/or father of the fetus under partial judicial protection

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Christel THAUVIN; 03.80.29.53.13 ext +33; christel.thauvin@chu-dijon.fr

• Listed Location Countries: France

Administrative Information

• NCT Number: NCT03964441
• Other Study ID Numbers: THAUVIN AnDDI rares 2018
• Has Data Monitoring Committee: Not Provided

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Centre Hospitalier Universitaire Dijon
• Original Responsible Party: Same as current
• Current Study Sponsor: Centre Hospitalier Universitaire Dijon
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Centre Hospitalier Universitaire Dijon
• Verification Date: July 2021